This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Senator Sanders’ proposal within PAHPA was ultimately struck from the next iteration of the legislation due to concerns from the pharmaceuticalindustry and others that such a measure would chill innovation. Federal support by BARDA and the CDC have de-risked the development of medical products for the pharmaceuticalindustry.
In fact, if you knew that the business model of PLM was always to package and sell data to researchers, including the pharmaceuticalindustry, you may shrug your shoulders and assume there is no fundamental change. But if you were not aware of that fact, you may be worried about who, exactly, now has access to the data.
Over time, these social movements may eventually secure increased public investment (pillar 2), as seen in Brazil, where the right to health played a role in directing the State towards a leading position in the national pharmaceuticalindustrial complex (pillar 3).
artwork by Daiara Tukano by Daiara Tukano and Maria Fernanda Gebara Last June, we had the honor of speaking at Law and Policy of Psychedelic Medicine, the 2024 Annual Conference hosted by the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School. You can watch our panel here.
artwork by Daiara Tukano by Daiara Tukano and Maria Fernanda Gebara Last June, we had the honor of speaking at Law and Policy of Psychedelic Medicine, the 2024 Annual Conference hosted by the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School. You can watch our panel here.
The reputation of the pharmaceuticalindustry gained a “whopping” 30 points between January 2020 and February 2021, based on the latest Harris Poll in their research into industries’ reputations. The study was written up by Beth Snyder Bulik in FiercePharma.
We organize all of the trending information in your field so you don't have to. Join 26,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content